Market Closed -
Nyse
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.82
USD
|
+5.81%
|
|
-1.09%
|
-54.27%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
250
|
117.4
|
140.3
|
65.04
|
24.2
|
29.37
|
-
|
-
|
Enterprise Value (EV)
1 |
250
|
117.4
|
140.3
|
65.04
|
24.2
|
29.37
|
29.37
|
29.37
|
P/E ratio
|
7.25
x
|
-5.12
x
|
-4.36
x
|
-1.85
x
|
-0.83
x
|
-1.1
x
|
-1.9
x
|
-4.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.15
x
|
995
x
|
-744
x
|
44.3
x
|
4.99
x
|
6.84
x
|
3.93
x
|
0.68
x
|
EV / Revenue
|
4.15
x
|
995
x
|
-744
x
|
44.3
x
|
4.99
x
|
6.84
x
|
3.93
x
|
0.68
x
|
EV / EBITDA
|
6,983,925
x
|
-4,985,872
x
|
-4,209,954
x
|
-
|
-752,220
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,622
|
9,170
|
9,202
|
9,271
|
11,523
|
16,137
|
-
|
-
|
Reference price
2 |
29.00
|
12.80
|
15.25
|
7.015
|
2.100
|
1.820
|
1.820
|
1.820
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
60.3
|
0.118
|
-0.1886
|
1.468
|
4.854
|
4.295
|
7.479
|
43.06
|
EBITDA
|
35.8
|
-23.54
|
-33.33
|
-
|
-32.17
|
-
|
-
|
-
|
EBIT
1 |
35.74
|
-23.61
|
-33.38
|
-36.59
|
-32.46
|
-20.71
|
-24.69
|
-12.37
|
Operating Margin
|
59.28%
|
-20,007.44%
|
17,701.01%
|
-2,491.62%
|
-668.75%
|
-482.32%
|
-330.14%
|
-28.73%
|
Earnings before Tax (EBT)
1 |
35.77
|
-22.43
|
-33.6
|
-36.2
|
-32.22
|
-29.04
|
-24.45
|
-12.17
|
Net income
1 |
35.77
|
-22.43
|
-33.6
|
-36.2
|
-27.54
|
-27.28
|
-21.23
|
-12.17
|
Net margin
|
59.32%
|
-19,006.71%
|
17,813.63%
|
-2,465.05%
|
-567.44%
|
-635.22%
|
-283.83%
|
-28.26%
|
EPS
2 |
4.000
|
-2.500
|
-3.500
|
-3.790
|
-2.530
|
-1.660
|
-0.9600
|
-0.3900
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
0.1595
|
0.3221
|
0.2161
|
0.7707
|
0.8696
|
1.026
|
1.196
|
1.762
|
2.106
|
2.034
|
0.0807
|
0.0873
|
0.314
|
0.346
|
7.88
|
EBITDA
1 |
-7.203
|
-8.424
|
-7.776
|
-
|
-8.693
|
-6.544
|
-7.223
|
-10.74
|
-6.022
|
1.258
|
-10.7
|
-11
|
-
|
-
|
-
|
EBIT
1 |
-7.216
|
-8.451
|
-7.82
|
-13.1
|
-8.753
|
-6.614
|
-7.301
|
-10.82
|
-6.109
|
1.173
|
-8.228
|
-7.55
|
-6.219
|
-6.611
|
0.47
|
Operating Margin
|
-4,524.55%
|
-2,623.45%
|
-3,618.88%
|
-1,699.81%
|
-1,006.46%
|
-644.39%
|
-610.64%
|
-613.99%
|
-290.07%
|
57.67%
|
-10,200.2%
|
-8,645.37%
|
-1,980.57%
|
-1,910.69%
|
5.96%
|
Earnings before Tax (EBT)
1 |
-7.113
|
-8.686
|
-7.632
|
-12.77
|
-8.255
|
-6.099
|
-7.148
|
-10.71
|
-5.888
|
-7.844
|
-8.977
|
-8.623
|
-6.171
|
-6.562
|
0.519
|
Net income
1 |
-7.113
|
-8.686
|
-7.632
|
-12.77
|
-8.255
|
-1.424
|
-7.148
|
-10.71
|
-5.888
|
-7.844
|
-8.394
|
-8.033
|
-6.171
|
-6.562
|
0.519
|
Net margin
|
-4,459.88%
|
-2,696.49%
|
-3,531.51%
|
-1,656.54%
|
-949.28%
|
-138.74%
|
-597.81%
|
-608.11%
|
-279.6%
|
-385.62%
|
-10,405.36%
|
-9,198.06%
|
-1,965.29%
|
-1,896.53%
|
6.59%
|
EPS
2 |
-0.7500
|
-1.000
|
-0.7500
|
-1.340
|
-0.8600
|
-0.1300
|
-0.6300
|
-0.9100
|
-0.4800
|
-0.5600
|
-0.4967
|
-0.4300
|
-0.2700
|
-0.2600
|
0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
2/14/22
|
5/16/22
|
9/22/22
|
11/14/22
|
2/14/23
|
5/15/23
|
9/28/23
|
11/14/23
|
2/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.06
|
0.01
|
0.26
|
0.43
|
0.04
|
0.19
|
-
|
Capex / Sales
|
-
|
53.29%
|
-3.03%
|
17.8%
|
8.94%
|
0.88%
|
2.55%
|
-
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Last Close Price
1.82
USD Average target price
9.333
USD Spread / Average Target +412.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -54.27% | 29.37M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|